Ireland
--:--IST
Recruiting Not applicable

Community Dining, Walking, and Glucose in Older Adults

NCT07695675 · tracked via the Priya Life Science China tracker
Sponsor
Phase
Not applicable
Started
2026-08-01
Last updated
2026-07-20

Condition(s) studied

Prediabetes

Investigational drug(s) / intervention(s)

Subsidized Community DiningHome Eating

Subsidized Community Dining: Participants will eat lunch and dinner at a subsidized community dining site for 6 days. No walking target or exercise prescription will be given. After each meal, participants will be free to walk, sit, rest, remain at the dining site, or return home according to their usual preference.

Home Eating: Participants will eat lunch and dinner at home for 6 days using a standardized Chinese meal rotation designed to approximate the energy and macronutrient composition of the community dining meals.

Study summary

This study will examine whether eating lunch and dinner at a subsidized community dining site affects postmeal walking and blood glucose patterns in older adults. Participants will be community-dwelling adults aged 60 to 79 years who are eligible for a local elderly meal subsidy and have prediabetes or elevated blood glucose risk.

Each participant will complete two 6-day meal conditions in random order. In one condition, participants will eat lunch and dinner at home. In the other condition, participants will eat lunch and dinner at a subsidized community dining site. Participants will wear a continuous glucose monitor and an activity tracker so the study team can measure postmeal glucose levels, daily glucose patterns, and steps after meals.

The study will compare community dining with home eating to determine whether community dining increases postmeal walking, improves postmeal glucose responses, and affects loneliness and meal experience.

Eligibility

Sex
ALL
Min age
60 Years
Max age
79 Years
Healthy volunteers
No
Inclusion Criteria: * Community-dwelling adults aged 60 to 79 years * Eligible for the local elderly meal subsidy * Prediabetes or elevated glycemic risk, defined as HbA1c 5.7% to 6.4% or fasting plasma glucose 100 to 125 mg/dL * Able to consume meals orally * Able to walk independently without a walking aid * Able to attend the community dining site safely * Able and willing to wear a continuous glucose monitor and activity tracker * Able and willing to follow the home-meal plan and study procedures * Able to provide written informed consent Exclusion Criteria: * HbA1c ≥6.5% or fasting plasma glucose ≥126 mg/dL * Diagnosed diabetes * Use of insulin or glucose-lowering medication * Severe cognitive impairment * Acute illness or recent hospitalization * Severe gastrointestinal disease affecting usual food intake or gastric emptying * Severe renal, hepatic, cardiovascular, or neurologic disease that would make participation unsafe * Skin conditions preventing continuous glucose monitor use * Food allergy or dietary restrictions incompatible with the standardized meal plan

Primary outcome measure(s)

  • Meal-Level 0- to 90-Minute Postprandial Glucose Incremental Area Under the Curve — Study Days 2-13; fixed premeal baseline window through 90 minutes after completion of each lunch and dinner during the 12-day randomized meal-condition period.
    Postprandial glucose incremental area under the curve (iAUC) will be calculated for each lunch and dinner from exported timestamped continuous glucose monitoring data using the trapezoidal rule. Baseline glucose will be defined as the mean continuous glucose monitoring value during the fixed 30-minute premeal baseline window. The postprandial calculation window will extend from meal completion through 90 minutes after meal completion.

Trial sites (1)

FacilityCityRegionStatus
Community Elderly Meal-Assistance Site Changsha Hunan Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07695675 on ClinicalTrials.gov ↗ ← All trials in China